Swiss Rockets AG, based in Basel, Switzerland, announced on February 23 that it entered into a definitive agreement to acquire Complete Genomics, Inc.
Complete Genomics is a leader in whole human genomic sequencing, which is used by research centers to conduct medical research that, in the future, is expected to be used to improve both prevention and treatment of disease. Since its founding in 2005, the company has been at the forefront of high-throughput, cost-effective sequencing innovation, supporting more than 10,900 scientific publications worldwide.
Swiss Rockets is a portfolio of biotechnology companies. Its portfolio includes radioligand therapies, small molecules and live-attenuated virus vaccines across preclinical and clinical stages.
The transaction will enable the scaling of the Complete Genomics innovation pipeline and diversification of manufacturing capacity. Terms were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 18th Biotechnology transaction of the year. There were 135 Biotechnology acquisitions reported in 2025, and 263 announced in 2024.
